Shuo Yang 1 , Andrew M Evens , Sheila Prachand , Amareshwar T K Singh , Savita Bhalla , Kevin David , Leo I Gordon . Show Affiliations »
Abstract
PURPOSE: Andrographolide is a diterpenoid lactone isolated from Andrographis paniculata (King of Bitters), an herbal medicine used in Asia. It has been reported to have anti-inflammatory, antihypertensive, antiviral, and immune-stimulant properties. Furthermore, it has been shown to inhibit cancer cell proliferation and induce apoptosis in leukemia and solid tumor cell lines. EXPERIMENTAL DESIGN: We studied the Burkitt p53-mutated Ramos cell line, the mantle cell lymphoma (MCL) line Granta, the follicular lymphoma (FL) cell line HF-1, and the diffuse large B-cell lymphoma (DLBCL) cell line SUDHL4, as well as primary cells from patients with FL, DLBCL, and MCL. RESULTS: We found that andrographolide resulted in dose- and time-dependent cell death as measured by MTT. Andrographolide significantly increased reactive oxygen species (ROS) production in all cell lines. To determine mechanism of cell death, we measured apoptosis by Annexin V/propidium iodide in the presence and absence of the antioxidant N-acetyl-l-cysteine (NAC), the glutathione (GSH)-depleting agent buthionine sulfoxamine (BSO), or caspase inhibitors. We found that apoptosis was greatly enhanced by BSO, blocked by NAC, and accompanied by poly(ADP-ribose) polymerase cleavage and activation of caspase-3, caspase-8, and caspase-9. We measured BAX conformational change and mitochondrial membrane potential, and using mouse embryonic fibroblast (MEF) Bax/Bak double knockouts (MEF(Bax-/-/Bak-/-)), we found that apoptosis was mediated through mitochondrial pathways, but dependent on caspases in both cell lines and patient samples. CONCLUSIONS: Andrographolide caused ROS-dependent apoptosis in lymphoma cell lines and in primary tumor samples, which was enhanced by depletion of GSH and inhibited by NAC or the pan-caspase inhibitor Z-VAD-FMK. Further studies of diterpenoid lactones in lymphoma are warranted. ©2010 AACR.
PURPOSE: Andrographolide is a diterpenoid lactone isolated from Andrographis paniculata (King of Bitters), an herbal medicine used in Asia. It has been reported to have anti-inflammatory, antihypertensive, antiviral, and immune-stimulant properties. Furthermore, it has been shown to inhibit cancer cell proliferation and induce apoptosis in leukemia and solid tumor cell lines. EXPERIMENTAL DESIGN: We studied the Burkitt p53 -mutated Ramos cell line, the mantle cell lymphoma (MCL ) line Granta, the follicular lymphoma (FL) cell line HF-1 , and the diffuse large B-cell lymphoma (DLBCL) cell line SUDHL4 , as well as primary cells from patients with FL, DLBCL, and MCL . RESULTS: We found that andrographolide resulted in dose- and time-dependent cell death as measured by MTT . Andrographolide significantly increased reactive oxygen species (ROS ) production in all cell lines. To determine mechanism of cell death, we measured apoptosis by Annexin V /propidium iodide in the presence and absence of the antioxidant N-acetyl-l-cysteine (NAC ), the glutathione (GSH )-depleting agent buthionine sulfoxamine (BSO ), or caspase inhibitors. We found that apoptosis was greatly enhanced by BSO , blocked by NAC , and accompanied by poly(ADP-ribose) polymerase cleavage and activation of caspase-3 , caspase-8 , and caspase-9 . We measured BAX conformational change and mito chondrial membrane potential, and using mouse embryonic fibroblast (MEF ) Bax /Bak double knockouts (MEF (Bax -/-/Bak -/-)), we found that apoptosis was mediated through mito chondrial pathways, but dependent on caspases in both cell lines and patient samples. CONCLUSIONS: Andrographolide caused ROS -dependent apoptosis in lymphoma cell lines and in primary tumor samples, which was enhanced by depletion of GSH and inhibited by NAC or the pan-caspase inhibitor Z-VAD-FMK . Further studies of diterpenoid lactones in lymphoma are warranted. ©2010 AACR.
Entities: CellLine
Chemical
Disease
Gene
Species
Mesh: See more »
Substances: See more »
Year: 2010
PMID: 20798229 PMCID: PMC2948634 DOI: 10.1158/1078-0432.CCR-10-0883
Source DB: PubMed Journal: Clin Cancer Res ISSN: 1078-0432 Impact factor: 12.531